摘要
Abstract
Objective To investigate the therapeutic effect of somatostatin combined with pantoprazole in the treatment of cirrhosis with upper gastrointestinal bleeding. Methods A total of 60 patients with cirrhosis and upper gastrointestinal bleeding admitted to the Department of Internal Medicine of the Second People's Hospital of Pulandian District, Dalian City from January 2017 to April 2018 were selected. The red and yellow balls were grouped, The red ball was the experimental group and the yellow ball was the control group, 30 cases in each group. The experimental group was treated with somatostatin and pantoprazole, and the control group was treated with somatostatin. The clinical treatment effect, hemostasis time, blood transfusion volume, time required for hospitalization, hemoglobin level, and total incidence of adverse reactions were observed in the two groups.Results The hemostasis time of the experimental group [ (23.62±4.92) vs (34.55±6.20) h], the transfusion volume [ (243.92±50.33) ml vs (492.39±55.20) ml], the time required for hospitalization [ (7.66±1.09) d vs (17.20±2.09) d], the total incidence of adverse reactions (6.67％ vs 30.00％) were lower than the control group, the difference was statistically significant (P ＜0.05) . The total effective rate of clinical treatment (86.67％ vs 60.00％) and hemoglobin level [ (120.60 ±15.00) g/L vs (103.01 ±15.37) g/L] were higher in the experimental group than in the control group, the difference was statistically significant (P＜0.05) . Conclusion Compared with single drug administration, the combination of somatostatin and pantoprazole in patients with cirrhosis and upper gastrointestinal hemorrhage is not only beneficial to improve the hemoglobin level, but also to reduce the amount of blood transfusion, hospitalization, adverse drug reactions, and thus improve treatment effect.关键词
生长抑素/泮托拉唑/肝硬化/上消化道出血Key words
Somatostatin/Pantoprazole/Cirrhosis/Upper gastrointestinal bleeding分类
医药卫生
